Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ALEC 
Alector Inc (ALEC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: ALEC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $2.2
1 Year Target Price $2.2
| 5 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -75.4% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 148.78M USD | Price to earnings Ratio - | 1Y Target Price 2.2 |
Price to earnings Ratio - | 1Y Target Price 2.2 | ||
Volume (30-day avg) 9 | Beta 0.99 | 52 Weeks Range 0.87 - 6.14 | Updated Date 11/1/2025 |
52 Weeks Range 0.87 - 6.14 | Updated Date 11/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -142.1% | Operating Margin (TTM) -433.55% |
Management Effectiveness
Return on Assets (TTM) -17.84% | Return on Equity (TTM) -103.99% |
Valuation
Trailing PE - | Forward PE 526.32 | Enterprise Value 52033959 | Price to Sales(TTM) 1.83 |
Enterprise Value 52033959 | Price to Sales(TTM) 1.83 | ||
Enterprise Value to Revenue 0.64 | Enterprise Value to EBITDA -8.4 | Shares Outstanding 101212329 | Shares Floating 84573022 |
Shares Outstanding 101212329 | Shares Floating 84573022 | ||
Percent Insiders 10.34 | Percent Institutions 77.06 |
Upturn AI SWOT
Alector Inc
Company Overview
History and Background
Alector Inc. was founded in 2013 and is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases.
Core Business Areas
- Immuno-Neurology Drug Development: Focuses on developing therapies that harness the power of the immune system to fight neurodegenerative diseases.
- Microglia Research: Alector is a leader in understanding the role of microglia, the brain's immune cells, in neurodegeneration.
- Target Validation and Discovery: Identify and validate novel targets implicated in neurodegenerative diseases and discover potential therapeutics against those targets.
Leadership and Structure
The leadership team includes prominent figures in the biotechnology and pharmaceutical industries. The organizational structure consists of research, development, clinical, and administrative departments.
Top Products and Market Share
Key Offerings
- AL001: Monoclonal antibody targeting SIGLEC3 (CD33) for Alzheimer's disease. Currently in clinical trials. Market share N/A due to pre-market status. Competitors: Roche (Gantenerumab), Biogen (Aduhelm).
- AL101: Kinase inhibitor targeting GRN-associated frontotemporal dementia (FTD-GRN). Currently in clinical trials. Market share N/A due to pre-market status. Competitors: No direct competitors currently, but Wave Life Sciences had a GRN program before shutting down, and Prevail Therapeutics (acquired by Eli Lilly) has PR006, an AAV9-based gene therapy, targeting GRN-associated FTD.
Market Dynamics
Industry Overview
The neurodegenerative disease market is large and growing due to an aging population. There is a high unmet need for effective treatments.
Positioning
Alector is positioned as a leader in the emerging field of immuno-neurology. Their focus on microglia sets them apart from many other companies in the space.
Total Addressable Market (TAM)
The TAM for neurodegenerative diseases is estimated to be hundreds of billions of dollars globally. Alector is positioned to capture a significant portion of this market with successful therapies.
Upturn SWOT Analysis
Strengths
- Pioneering immuno-neurology approach
- Strong expertise in microglia biology
- Promising pipeline of clinical-stage drug candidates
- Strategic partnerships with major pharmaceutical companies
Weaknesses
- High risk associated with drug development
- Reliance on clinical trial success
- Limited revenue stream
- Cash burn rate
Opportunities
- Expanding pipeline to address other neurodegenerative diseases
- Partnering with other companies to accelerate development
- Securing regulatory approval for lead drug candidates
- Developing novel diagnostic tools for early disease detection
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Economic downturn affecting funding
Competitors and Market Share
Key Competitors
- Biogen (BIIB)
- Roche (RHHBY)
- Eli Lilly (LLY)
Competitive Landscape
Alector has a strong focus on immuno-neurology which distinguishes them from competitors. Alector is in the clinical stage. Their competitive advantage lies in their targeted approach to modulating the immune system in the brain.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is represented by the progression of its drug candidates through clinical trials and the expansion of its research programs.
Future Projections: Future growth is dependent on successful clinical trials and regulatory approvals. Analyst estimates are variable and based on projections for key drug candidates.
Recent Initiatives: Recent initiatives include advancing its clinical trials, expanding collaborations, and presenting data at scientific conferences.
Summary
Alector is a clinical-stage biotechnology company focused on immuno-neurology which is a risk but could be rewarding. Their core strength lies in their specialized understanding of microglia and targeted therapeutics. They are positioned in the large neurodegenerative disease market. Their financial performance depends on clinical trial successes, strategic partnerships, and market acceptance of their therapeutics, where clinical failure is a threat.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Alector Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alector Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2019-02-07 | Co-Founder, CEO & Director Dr. Arnon Rosenthal Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 163 | Website https://www.alector.com |
Full time employees 163 | Website https://www.alector.com | ||
Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. The company's products under development include Latozinemab (AL001), an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain. Its lead PGRN-elevating candidate is being developed for the potential treatment of frontotemporal dementia with a granulin gene mutation (FTD-GRN) which is caused by heterozygous loss-of-function (LOF) mutations in the GRN gene and results in PGRN haploinsufficiency and is in Phase 3 clinical trial. It also develops AL101/GSK4527226 that is in Phase 2 clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. In addition, the company's preclinical and research pipeline products include ADP037-ABC, a proprietary anti-amyloid beta (Aß) antibody paired with proprietary ABC for the treatment of AD; ADP050-ABC, a GCase replacement therapy paired with proprietary ABC for GBA gene mutation carriers with Parkinson's disease and Lewy body dementia; ADP056, a Reelin modulator designed to block tau pathology and promote synaptic function in AD; and ADP063-ABC and ADP064-ABC that are therapeutic candidates paired with proprietary ABC that target tau pathology in AD through distinct approaches. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.